financetom
Business
financetom
/
Business
/
Volvo Cars to start mid-size SUV production at US plant next year
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Volvo Cars to start mid-size SUV production at US plant next year
Jul 16, 2025 11:27 AM

(Reuters) -Sweden's Volvo Cars said on Wednesday it would start producing its XC60 mid-size SUV in its plant in South Carolina, United States from late 2026.

The shift highlights the automaker's exposure to U.S. President Donald Trump's auto tariffs, as it imports most of its hybrid and electric models from Europe.

XC60's sales in the United States rose by almost 23% in the first six months of 2025, the Gothenburg-based company said, adding that the model was most popular among U.S. customers.

Volvo Cars, which is owned by China's Geely Holding, had said earlier this week that it was booking an impairment charge of 11.4 billion crowns ($1.17 billion) in the second quarter related to its ES90 and EX90 models due to tariffs and launch delays.

Most of Volvo Cars' vehicles for the U.S. market, which last year accounted for 16% of group sales, are imported from Europe. The company only produces its high-end SUV EX90, at the Charleston, South Carolina factory. CEO Hakan Samuelsson has earlier said that a popular hybrid model was needed to be added to the plant.

The company's CEO had said earlier in April that the carmaker would produce more cars in the U.S, while also ramping its regionalisation efforts.

Samuelsson had told Swedish newspaper Dagens Nyheter (DN) that Volvo Cars would need up to two years to expand its U.S. car production. "In the short term, within one to two years, it will be about selling the cars we have," he said to DN, adding the situation would put pressure on profit margins but that customers will also have to pay more.

($1 = 9.7057 Swedish crowns)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mirum Pharmaceuticals Insider Sold Shares Worth $320,644, According to a Recent SEC Filing
Mirum Pharmaceuticals Insider Sold Shares Worth $320,644, According to a Recent SEC Filing
Jan 8, 2025
04:48 PM EST, 01/08/2025 (MT Newswires) -- Christopher Peetz, Director, CEO, on January 07, 2025, sold 7,489 shares in Mirum Pharmaceuticals ( MIRM ) for $320,644. Following the Form 4 filing with the SEC, Peetz has control over a total of 327,929 shares of the company, with 119,359 shares held directly and 208,570 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1759425/000141588925001143/xslF345X05/form4-01082025_090146.xml ...
Nuvalent Insider Sold Shares Worth $320,009, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $320,009, According to a Recent SEC Filing
Jan 8, 2025
04:53 PM EST, 01/08/2025 (MT Newswires) -- Alexandra Balcom, Chief Financial Officer, on January 06, 2025, sold 4,016 shares in Nuvalent ( NUVL ) for $320,009. Following the Form 4 filing with the SEC, Balcom has control over a total of 61,734 shares of the company, with 61,734 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1861560/000095017025003483/xslF345X05/ownership.xml ...
Marvell Technology Insider Sold Shares Worth $613,250, According to a Recent SEC Filing
Marvell Technology Insider Sold Shares Worth $613,250, According to a Recent SEC Filing
Jan 8, 2025
04:56 PM EST, 01/08/2025 (MT Newswires) -- Michael G Strachan, Director, on January 06, 2025, sold 5,000 shares in Marvell Technology ( MRVL ) for $613,250. Following the Form 4 filing with the SEC, Strachan has control over a total of 51,649 shares of the company, with 51,649 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1835632/000183563225000003/xslF345X05/wk-form4_1736373277.xml ...
NeuroPace Preliminary Q4 Revenue Increases; Shares Rise After Hours
NeuroPace Preliminary Q4 Revenue Increases; Shares Rise After Hours
Jan 8, 2025
04:49 PM EST, 01/08/2025 (MT Newswires) -- NeuroPace ( NPCE ) reported preliminary Q4 revenue late Wednesday in the range of $21 million to $21.5 million, up from $18 million a year earlier. Analysts polled by FactSet expect $20.9 million. Shares of the company rose 4.2% in recent after-hours activity. Price: 12.51, Change: +0.50, Percent Change: +4.16 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved